Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Indomethacin  COVID-19 treatment studies for Indomethacin  C19 studies: Indomethacin  Indomethacin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Indomethacin for COVID-19
4 studies from 333 scientists
605 patients in 3 countries
Statistically significant improvement for recovery.
2 studies (both from the same team) show statistically significant improvements in isolation.
COVID-19 Indomethacin studies. Feb 2023.
0 0.5 1 1.5+ All studies 74% Hospitalization 67% Recovery 34% Viral clearance 17% RCTs 30% Late 74% Favorsindomethacin Favorscontrol
Indomethacin COVID-19 studies. Indomethacin may be beneficial for cough [Alkotaji], which may not respond to other treatments. Recent:
Submit updates/corrections.
Feb 1
Covid Analysis (Preprint) (meta analysis) Indomethacin for COVID-19: real-time meta analysis of 4 studies
Statistically significant improvement is seen for recovery. 2 studies (both from the same team) show statistically significant improvements in isolation. • Meta analysis using the most serious outcome reported shows 74% [-20‑..
Jun 30
Chakraborty et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105788 In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2
In Silico study predicting indomethacin and vitamin A can bind critical host and viral proteins for SARS-CoV-2 interaction, and may be able to compensate for gene expressions changes related to SARS-CoV-2.
Apr 19
Ravichandran et al., Scientific Reports, doi:10.1038/s41598-022-10370-1 An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
30% improved recovery [p=0.002], 98% lower progression [p<0.0001], and 17% improved viral clearance [p=0.19]. RCT with 103 indomethacin and 107 paracetamol patients, showing lower progression and improved recovery with indomethacin. Notably, improvements include faster resolution of cough. [Alkotaji] previously hypothesised the benefit of indomet..
Jan 13
Salmasi et al., Immunopathologia Persa, doi:10.34172/ipp.2022.xx Efficacy of oral indomethacin in the treatment of COVID-19 infection; a randomized clinical trial
66% lower ventilation [p=1] and 40% slower recovery [p=0.52]. Very small RCT with 22 indomethacin and 23 control patients, showing no significant difference in outcomes. All patients were treated with HCQ.
Dec 8
Fazio et al., Medical Science Monitor, doi:10.12659/MSM.935379 Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021
Retrospective 158 COVID-19 patients in Italy treated with hesperidin, quercetin, indomethacin, aspirin, omeprazole, azithromycin, LMWH, and betamethasone (treatment specific for each patient), showing significantly lower hospitalization a..
Jul 31
Ravichandran et al., J. Indian Med. Assoc., 119:7 Use of indomethacin in COVID-19 patients: experience from two medical centres
96% lower need for oxygen therapy [p<0.0001] and 43% faster recovery [p<0.0001]. PSM retrospective 72 indomethacin and 72 paracetamol patients in India, showing lower progression and improved recovery with indomethacin.
Apr 22
Alkotaji et al., Current Pharmacology Reports, doi:10.1007/s40495-021-00257-6 (Theory) Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?
Hypothesis that indomethacin will be beneficial for COVID-19 induced dry cough, via inhibition of the cyclooxygenase enzyme and reducing the level of inflammatory mediator bradykinin.
Dec 4
Gordon et al., Science, doi:10.1126/science.abe9403 Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
67% lower hospitalization [p=0.34] and 57% lower progression [p=0.21]. Analysis of interactions between viral and human proteins for SARS-CoV-2, SARS-CoV-1, and MERS-CoV and genetic screening to identify host factors that enhance or inhibit viral infection. Authors predict indomethacin will have antiviral ac..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.